Alzamend Neuro, Inc. ALZN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 102.17% | 253.79% | 55.68% | -21.51% | 26.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.04% | 152.08% | 111.85% | -26.51% | 180.57% |
| Operating Income | -12.04% | -152.08% | -111.85% | 26.51% | -180.57% |
| Income Before Tax | -12.00% | -151.88% | -111.56% | 26.50% | -177.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.00% | -151.88% | -111.56% | 26.50% | -177.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.00% | -151.88% | -111.56% | 26.50% | -177.37% |
| EBIT | -12.04% | -152.08% | -111.85% | 26.51% | -180.57% |
| EBITDA | -12.17% | -152.44% | -111.77% | 27.87% | -181.40% |
| EPS Basic | 47.33% | 68.64% | 67.04% | 91.47% | 88.76% |
| Normalized Basic EPS | 47.34% | 54.81% | 65.98% | 91.47% | 88.76% |
| EPS Diluted | 47.33% | 68.64% | 67.04% | 91.47% | 88.76% |
| Normalized Diluted EPS | 47.34% | 54.81% | 65.98% | 91.47% | 88.76% |
| Average Basic Shares Outstanding | 112.66% | 457.28% | 521.68% | 761.62% | 2,368.93% |
| Average Diluted Shares Outstanding | 112.66% | 457.28% | 521.68% | 761.62% | 2,368.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |